Biolife Solutions Inc (NASDAQ: BLFS)

BioLife Solutions Inc develops, manufactures, and markets bioproduction products and services designed to improve the quality and de-risk the manufacturing, distribution, and transportation of biologic materials in the cell and gene therapy (CGT) industry. The company operates in the life sciences sector, focusing on biopreservation media and cell processing products that maintain the health and function of biologic material during sourcing, manufacturing, and distribution.

BioLife Solutions generates revenue through the sale of its bioproduction products and services, which include cell processing and other products, biopreservation media, human platelet lysate media, cryogenic and ultralow temperature containers, automated cell-processing fill machines, and automated thawing devices. The company's primary customer base consists of academic research institutions, clinical practices, and biopharma companies involved in the development and manufacturing of biologic-based therapies.

• Cell processing and other products: This segment includes a range of products such as CellSeal closed systems, CryoCase cryo-compatible transparent rigid containers, and automated cell processing machines. These products are designed for use in the CGT market, providing solutions for cell processing and storage.

• Biopreservation media: BioLife Solutions offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media. These products are formulated to mitigate preservation-induced cell damage and death, extending the shelf life and improving post-preservation cell and tissue viability and function. The media are serum-free, protein-free, fully defined, and manufactured under current Good Manufacturing Practices (cGMP).

• Human platelet lysate media, cryogenic vials, and automated cell-processing fill machines: This segment includes human platelet lysates for cell expansion, which reduce risk and improve downstream performance over fetal bovine serum and other media. It also encompasses CellSeal closed systems, CryoCase cryo-compatible transparent rigid containers, and automated cell processing machines designed for high-throughput processing and protection of therapies from loss or contamination.

• Automated thawing devices: The ThawSTAR line of products controls the temperature and timing of the thawing process of biologic material. These customizable, automated, water-free thawing products use algorithmic programmed heating plates to consistently bring biologic material from a frozen state to a liquid state, reducing damage during temperature transitions and delivering critical process consistency across cell batches.

BioLife Solutions holds a strong position within the CGT industry, which has been rapidly expanding, treating diseases once thought incurable. The company's competitive advantages include its proprietary biopreservation media formulations, which offer significant advantages over traditional media and in-house formulations. These advantages include time savings, more consistent and higher quality of components, more rigorous quality control release testing, cost-effectiveness, and improved preservation efficacy. The company's products have demonstrated improved biopreservation outcomes, including greatly extended shelf-life and post-thaw viability and yield across a broad array of cell and tissue types. BioLife Solutions competes with numerous established technologies and companies, many of which have greater financial and human resources. However, the company's focus on innovation, quality, and customer service positions it well within the industry.

The company's customer base is diverse, including academic research institutions, clinical practices, and biopharma companies involved in the development and manufacturing of biologic-based therapies. BioLife Solutions serves customers globally, with a significant portion of its revenue coming from the United States, followed by Europe, the Middle East, Africa, and other regions. The company's products are used in several hundred active clinical trials worldwide, highlighting their importance in the CGT field.